TSHA

Healthcare Biotechnology

Taysha Gene Therapies, Inc.

$4.63

-0.15 -3.14% today

Price History

Not enough data

Key Stats

Market Cap

1.51B

Avg Volume

3.16M

EPS

-$0.41

52W High

$7.30

52W Low

$3.69

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-10.01

P/B Ratio

3.89

P/S Ratio

275.04

EV/EBITDA

-7.30

EV/Revenue

202.35

Margins

Gross Margin 100.0%

Operating Margin (2792.3%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(47.1%)

Return on Assets

(23.8%)

Liquidity & Leverage

Current Ratio

17.77

Quick Ratio

17.53

Debt / Equity

0.15

Total Cash

455.41M

Total Debt

56.71M

About

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.